Ethical and Legal considerations in Clinical Trial Design [Poster]

Abstract

The ethical and legal framework for clinical trials in the European Union ensures research aligns with moral obligations and regulatory standards. Key trial types, such as Randomized Controlled Trials, Adaptive Trials, and Pragmatic Trials, each present unique challenges. The EU Clinical Trials Regulation harmonizes research across member states, emphasizing participant safety, informed consent, and transparency. These regulations, along with the European Medicine's Agency Good Clinical Practice guidelines and the WMA Declaration of Helsinki , shape ethical trial design. RCTs must maintain equipoise , ensuring genuine uncertainty about treatment superiority. Ethical concerns arise when placebo use may deny effective treatment, impacting participant welfare. Adaptive trials offer flexibility but challenge informed consent, as protocols may change based on interim data. Pragmatic Trials, conducted in real-world settings, provide valuable insights but raise concerns about maintaining ethical rigour. The EU’s centralized approval process via the Clinical Trials Information System streamlines multi-country trials. In contrast, the USA relies on a decentralized system overseen by Institutional Review Boards. Cases like Grimes v. Kennedy Krieger Institute in the USA and Olainfarm AS v. Latvia in the EU are examples of how courts interpret and enforce these regulations, reflecting the practical application and evolving interpretation of legal standards. Understanding this distinction is essential for comprehending how regulations are not static but are continually shaped by judicial decisions.